Vilacto Bio (VIBI) 10-K 10 Jul 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2019	Jun. 19, 2019
Document And Entity Information
Entity Registrant Name	Vilacto Bio Inc.
Entity Central Index Key	0001576724
Document Type	10-K
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Public Float		$ 1,787,022,235
Entity Common Stock, Shares Outstanding		1,917,431,324
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Shell Company	false

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current assets
Cash	$ 257,218	$ 148,767
Accounts receivable	23	36
Inventory	119,045	100,413
Prepaid expenses		59,658
Total current assets	376,286	308,874
Fixed assets, net	11,302
Intangible assets, net	150,080	896
Total assets	537,668	309,770
Current liabilities
Accounts payable and accrued liabilities	76,023	35,780
Due to related parties	176,026	240,952
Convertible loans	274,688	32,607
Derivative liabilities	1,227,041	729,737
Loans	174,000	174,000
Loans from related parties	2,032,608	32,608
Total current liabilities	3,960,386	1,245,684
Total liabilities	3,960,386	1,245,684
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding as of March 31, 2019 and March 31, 2018, respectively	3,000
Common stock; $0.001 par value; 4,000,000,000 shares authorized; 597,064,715 and 90,000,000 shares issued and outstanding as of March 31, 2019 and March 31, 2018, respectively	$ 597,065	$ 90,000
Stock payable	15,029
Additional paid-in capital	$ 3,820,233	$ (22,000)
Accumulated earnings (deficit)	(7,858,045)	(1,003,914)
Total stockholders' equity (deficit)	(3,422,718)	(935,914)
Total liabilities and stockholders' equity (deficit)	$ 537,668	$ 309,770

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
Stockholders' equity
Common stock, par value	$ 0.001	$ 0.001
Common stock shares, authorized	4,000,000,000	1,125,000,000
Common stock shares, issued	597,064,715	90,000,000
Common stock shares, outstanding	597,064,715	90,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares, authorized	10,000,000
Preferred stock shares, issued	3,000,000
Preferred stock shares, outstanding	3,000,000

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenues	$ 4,894	$ 1,429
Cost of revenues	4,043	583
Gross profit	851	846
Operating expenses
Royalty expense	80,000	120,000
Professional fees		153,104
General and administrative expenses	299,781	109,263
Depreciation and amortization expense	9,012	24
Total operating expenses	970,890	382,391
Loss from operations	(970,039)	(381,545)
Other income (expense)
Gain (loss) on derivative liabilities	(1,465,183)	(467,237)
Loss on disposal of assets	(6,118)
Loss on acquisition of related party assets	(3,242,070)
Loss on debt modification	(37,500)
Interest expense	(1,133,221)	(44,335)
Total other income (expense)	$ 5,884,092	511,572
Net income (loss)		$ (893,117)
Basic income (loss) per common share	$ (0.05)	$ (0.01)
Basic weighted average common shares outstanding	127,714,862	90,000,000

Shareholders Equity (Unaudited)

Shareholders Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Stock Payable	Accumulated Deficit	Total
Beginning Balance, Shares at Mar. 31, 2017		90,000,000
Beginning Balance, Amount at Mar. 31, 2017		$ 90,000	$ (22,000)		$ (110,797)	$ (42,797)
Net loss for the period					$ (893,117)	(893,117)
Ending Balance, Amount at Mar. 31, 2018		$ 90,000,000				$ (935,914)
Ending Balance, Shares at Mar. 31, 2018		90,000	(22,000)		(1,003,914)	935,914
Shares issued to related party to acquire intangible assets, shares		8,500,000
Shares issued to related party to acquire intangible assets, amount		$ 8,500	$ 1,368,500			$ 1,377,000
Shares issued upon conversion of debts, shares		480,155,626
Shares issued upon conversion of debts, amount		$ 480,156	2,021,142	15,029		2,516,327
Shares issued for services, shares		48,409,089
Shares issued for services, amount		$ 48,409	425,591			474,000
Common stock exchanged for preferred stock, shares	3,000,000	(30,000,000)
Common stock exchanged for preferred stock, amount	$ 3,000	$ (30,000)	27,000
Net loss for the period					$ (6,854,131)
Ending Balance, Amount at Mar. 31, 2019	$ 3,000,000	$ 597,064,715				$ (3,422,718)
Ending Balance, Shares at Mar. 31, 2019	3,000	597,065	3,820,233	15,029	(7,858,045)	3,422,718

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows from Operating Activities
Net income (loss)		$ (893,117)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	$ 9,012	24
Loss on acquisition of related party assets	3,242,070
Loss on derivative liability	1,465,183	467,237
Loss on disposal of assets	6,118
Loss on debt modification	37,500
Stock based compensation	474,000
Penalties on convertible debts	120,533
Amortization of debt discount	845,023	32,607
Changes in assets and liabilities
(Increase) decrease in accounts receivable	13	(36)
(Increase) decrease in prepaid expense	59,658	(59,433)
(Increase) decrease in inventory	(18,632)	(100,413)
Increase (decrease) in accounts payable	12,500	215,123
Net cash from operating activities	(601,153)	(338,008)
Cash Flows from investing
Purchase of fixed assets	(19,292)
Purchase of intangible assets	21,394	920
Net cash used in investing activities	(40,686)	(920)
Cash Flows from Financing Activities
Proceeds from promissory notes		151,500
Proceeds from convertible notes, net of debt issuance costs	792,550	262,500
Payments on convertible notes	(60,000)
Payments on advance from related parties		51,214
Advance from related parties	17,740	102,890
Net cash from financing activities	750,290	465,676
Net increase (decrease) in Cash	108,451	126,748
Beginning cash balance	148,767	22,020
Ending cash balance	257,218	148,768
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for tax

Organization and Line Business

Organization and Line Business	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND LINE BUSINESS	1. ORGANIZATION AND LINE BUSINESS The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013. The Company is devoting substantially all of its present efforts to establish a new business and has had minimal revenues from operations to date. On April 4, 2017, the Company entered into a license agreement (the “License Agreement”) with Pharma GP APS, a Company controlled by our CEO. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. As a result of the License Agreement, the Company is currently marketing a line of skin care products on its website at www.vilacto.com. These products include, lotions, skin care creams and gels, lip balms, foot creams and oils, and similar items. On November 8, 2018, we entered into an Asset Purchase Agreement with 9 Heroes APS, a Denmark corporation that is controlled by our CEO, Gert Andersen, to purchase certain patents applications and intellectual property. We formed a new wholly owned subsidiary, Vilacto BioIP, LLC, to hold the assets acquired in the Asset Purchase Agreement. (See Note 6 for additional details) The patent applications and intellectual property include the following: United States Patent Application # 8,637,075 entitled “Colostrum Composition”; European Patent Application # EP2341916 entitled “Colostrum Composition”; Hong Kong Patent Application # HK1159997 entitled “Colostrum Composition”; and Canada Patent Application # 2,773,277 entitled “Colostrum Composition.” We plan to use the assets acquired to expand the reach of our opportunities in doing business internationally. By acquiring these patent applications, we are better presented as a company with international IP solutions, which we believe will make us more attractive as an international biotech/pharma company and developer.

Basis of Presentation and Going

Basis of Presentation and Going Concern	12 Months Ended
	Mar. 31, 2019
BASIS OF PRESENTATION AND GOING CONCERN	2. BASIS OF PRESENTATION AND GOING CONCERN The accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the period presented have been reflected herein. Going concern

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2019
Basis of Presentation	3. SUMMARY OF SIGNIFICANT POLICIES This summary of significant accounting policies of Vilacto Bio Inc. is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Revenue Recognition In situations where arrangements include customer acceptance provisions based on seller or customer-specified objective criteria, we recognize revenue when we have concluded that the customer has control of the goods and that acceptance is likely to occur. We generally do not provide for anticipated losses on point in time transactions prior to transferring control of the equipment to the customer. For the years ended March 31, 2019 and 2018 the Company reported revenues of $4,894 and $1,429 respectively, respectively. Accounts Receivable Cash and cash equivalents Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of March 31, 2019, the cash balance in excess of the FDIC limits was $4,871. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts. Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity). Stock-based compensation Compensation-Stock Compensation, Non-Employee Stock Based Compensation Earnings (loss) per share Earnings Per Share, Long-lived Assets Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms in agreements are reviewed to determine whether or not they contain embedded derivatives that are required under ASC 815 to be accounted for and separated from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities is required to be revalued at each reporting date, with the corresponding changes in fair value recorded in current period operating results. Inventory Income taxes Income Taxes Segment Reporting Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASC 842 effective April 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on April 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

Inventory

Inventory	12 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
INVENTORY	4. INVENTORY Inventory consist of the following as of March 31, 2019 and March 31, 2018: March 31, 2019 March 31, 2018 Raw materials $ — $ — Finished Goods 119,045 100,413 Total $ 119,045 $ 100,413

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Mar. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES	5. PREPAID EXPENSES Prepaid expenses consist of the following as of March 31, 2019 and March 31, 2018: March 31, 2019 March 31, 2018 Prepaid Marketing $ — $ 59,568 Total prepaid expenses $ — $ 59,568

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. Intangible assets consist of the following as of March 31, 2019 and March 31, 2018: March 31, 2019 March 31, 2018 Patents and trademarks $ 135,850 $ 920 Website 21,394 — Less: accumulated amortization (7,164 ) (24) Intangible assets, net of accumulated amortization $ 150,080 $ 896 Amortization expense for the years ended March 31, 2019 and 2018 was $7,164 and $24, respectively. On November 8, 2018, we entered into an Asset Purchase Agreement with 9 Heroes APS, a Denmark corporation that is controlled by our CEO, Gert Andersen, to purchase certain patents applications and intellectual property. We formed a new wholly owned subsidiary, Vilacto BioIP, LLC, to hold the assets acquired in the Asset Purchase Agreement. The patent applications and intellectual property include the following: United States Patent Application # 8,637,075 entitled “Colostrum Composition”; European Patent Application # EP2341916 entitled “Colostrum Composition”; Hong Kong Patent Application # HK1159997 entitled “Colostrum Composition”; and Canada Patent Application # 2,773,277 entitled “Colostrum Composition.” These patent applications are describing the particle, development and use, of a nanoparticle composition comprised of (1) colostrum and (2) at least one agent selected from a group of hydrocolloids , such as hyaluronic acid, which is useable for a wide range of applications. We also secured domains names including Lactoactive and Vilact. In consideration for the assets, we agreed to pay 9 Heroes APS the purchase price of $3,360,000 USD, payable in an 8% secured promissory note (the “Note”) with a face amount of $2,000,000 and the balance in our common stock, consisting of 8,500,000 shares of our common stock. We closed the transaction on November 8, 2018. In accordance with US GAAP the Company recorded the assets on the books of the Company at costs basis due to fact that our CEO commonly controlled both entities involved in the transaction. The difference between the historical costs basis of the assets and the fair value of the consideration paid has been recorded as a loss on assets acquired from related parties of $3,242,070. The Note matures in five years from execution. Interest is due and payable on a semiannual basis with the first payment due on January 1, 2019 and future payments due every six-months afterwards until maturity. At the sole option of the note holder interest may be converted into the Company’s common stock. The conversion price shall be equal to the average of the closing market prices for the Company’s common stock on the OTCQB during the five (5) trading days immediately preceding the due date for such payment. We plan to use the assets acquired to expand the reach of our opportunities in doing business internationally. We currently only have a license from Pharma GP to reach customers in the United States. By acquiring these patent applications, we are better presented as a company with international IP solutions, which we believe will make us more attractive as an international biotech/pharma company and developer.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	7. CONVERTIBLE NOTES PAYABLE Convertible Notes Payable at consists of the following: March 31, March 31, 2019 2018 Auctus Fund, LLC On February 26, 2018, we entered into a Securities Purchase Agreement (the “Auctus SPA”), under which we agreed to sell a 12% convertible promissory note in an aggregate principal amount of $167,750 (the “Auctus Note”) to Auctus Fund, LLC (“Auctus”). The Auctus Note bears interest at a rate of 12% per annum and matured on November 26, 2018. The net proceeds of the sale of the Auctus Note, after deducting the expenses payable, were $150,000. At any time after the issue date of the Auctus Note, Auctus has the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Auctus Note into shares of our common stock at the Conversion Price. The “Conversion Price” is the lesser of (i) the lowest trading price of our common stock during the twenty-five-day trading period prior to the issue date of the Auctus Note and (ii) 50% of the lowest trading price of our common stock during the twenty-five-day trading period prior to the conversion. The Conversion Price is subject to further reduction upon certain events specified in the Auctus Note. We have the right to prepay the Auctus Note at any time until the 180th calendar day after the issue date of the Auctus Note, in an amount equal to 150% (or 135% if we prepay the Auctus Note on or before the date that is 90 days after the issue date of the Auctus Note) of the outstanding balance of the Auctus Note (including principal and accrued and unpaid interest). We may not prepay the Auctus Note after the 180th calendar day after the issue date of the Auctus Note. We will be subject to a liquidated damages charge of 25% of the outstanding principal amount of the Auctus Note if we effect certain exchange transactions in accordance with, based upon or related or pursuant to Section 3(a)(10) of the Securities Act. In addition, the Auctus Note grants Auctus the right to update the terms of the Auctus SPA and the Auctus Note to incorporate the terms of any future transaction document related to a security issuance by us to a third party that are more favorable to the third party than the terms of the Auctus SPA and the Auctus Note. Any amounts due and payable to Auctus under the terms of the Auctus Note, including any payment on an event of default, default interest, or agreed upon liquidated damages may, at the Auctus's option, be converted into shares of our common stock at the Conversion Price. Pursuant to a Registration Rights Agreement, we are required to register 30,000,000 shares into which the Auctus Note may be converted. As of March 31, 2019 the note holder had converted $87,352 in Principal and $25,417 in interest and fees into 74,645,400 shares of the Company’s common stock. (See note 9 for additional details.) During the year ended March 31, 2019 the Company recorded interest of $23,597. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $147,472 during the year ended March 31, 2019. $ 80,398 167,750 Unamortized debt discount - (147,472) Total, net of unamortized discount 80,398 20,278 EMA Financial, LLC On February 23, 2018 we entered into a Securities Purchase Agreement (“EMA SPA”) with EMA Financial, LLC, a Delaware limited liability company (“EMA”), pursuant to which we issued and sold to EMA a convertible promissory note, dated February 23, 2018 in the principal amount of $125,000 (the “EMA Note”). In connection with the foregoing, we also entered into a Registration Rights Agreement with the Purchaser dated February 23, 2018 (the “Registration Rights Agreement”). The EMA Note, as amended, was due February 23, 2019 and bears interest at the rate of 12% per annum. All principal and accrued interest on the EMA Note is convertible into shares of our common stock at the election of EMA at any time at a conversion price equal to the lesser of (i) the trading price for our common stock on the trading day prior to the closing date of the EMA Note, or (ii) a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have no right to prepay the EMA Note more than 180 days after the closing date. The EMA Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. As a result of claimed defaults, the promissory notes discount conversion rate was increased to a 80% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion On July 6, 2018, the Company executed an amendment to the promissory note to cure certain events of default in which it agreed to increase the principal balance of the note by $37,500 and pay $25,000 in principal to the lender within 5 days of execution of the amendment. The company treated the amendment as a debt modification under ASC 470 and recorded a corresponding loss on debt modification of $37,500. During the year ended March 31, 2019 the Company incurred additional penalties of approximately $120,533 which were added to the principal total owed under the promissory note. As of March 31, 2019, the note holder had converted $146,316 in Principal and $16,830 in interest and fees into 115,350,000 shares of the Company’s common stock. (See note 9 for additional details.) During the year ended March 31, 2019 the Company recorded interest of $13,614. In July 2018, the Company made a cash payment of principal and interest of $60,000 on the then outstanding balance. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $150,171 during the year ended March 31, 2019. 76,717 125,000 Unamortized debt discount - (112,671) Total, net of unamortized discount 76,717 12,329 Adar Bays, LLC July 2, 2018 Secured Convertible Note On July 2, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 2, 2018 in the principal amount of $150,000 (the “July 2, 2018 Adar Note”). The July 2, 2018 Adar Note is due July 2, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the July 2, 2018 Adar Note is convertible into shares of our common stock at the election of Adar six months after the issuance date at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We can pay the note in cash within the first six months of issuance, we have no right to prepay the July 2, 2018 Adar Note six months and one day after issuance. The July 2, 2018 Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $9,314. As of March 31, 2019, the note holder had converted $150,000 in Principal into 90,272,841 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $150,000 during the year ended March 31, 2019. - - Unamortized debt discount - - Total, net of unamortized discount - - GS Capital Partners, LLC Convertible Note On July 11, 2018 we entered into a Convertible note with GS Capital Bays, LLC (“GS”) pursuant to which we issued a convertible promissory note, dated July 11, 2018 in the principal amount of $110,000 (the “GS Note”). The GS Note is due July 11, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the GS Note is convertible into shares of our common stock at the election of GS at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the GS Note within 60 days of the closing date at a premium of 125% of all amounts owed to GS and at a premium of 135% if prepaid more than 60 but less than 120 days following the closing date, at a premium of 145% if prepaid more than 120 but less than 180 days following the closing date. We have no right to prepay the GS Note more than 180 days after the closing date. The GS Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $7,113 As of March 31, 2019, the note holder had converted $92,000 in Principal and $5,733 in interest and fees into 65,369,262 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $92,000 during the year ended March 31, 2019. 18,000 - Unamortized debt discount (18,000) - Total, net of unamortized discount - - Eagle Equities, LLC Convertible Note On July 20, 2018 we entered into a Convertible note with Eagle Equities, LLC (“Eagle”) pursuant to which we issued a convertible promissory note, dated July 20, 2018 in the principal amount of $100,000 (the “Eagle Note”). The Eagle Note is due July 20, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Eagle Note is convertible into shares of our common stock at the election of Eagle at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Eagle Note within 90 days of the closing date at a premium of 135% of all amounts owed to GS and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Eagle Note more than 180 days after the closing date. The Eagle Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $5,913. As of March 31, 2019, the note holder had converted $100,000 in Principal and $5,911 in interest and fees into 68,419,200 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $100,000 during the year ended March 31, 2019. - - Unamortized debt discount - - Total, net of unamortized discount - - Adar Bays, LLC July 23, 2018 Secured Convertible Note On July 23, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 23, 2018, in the principal amount of $50,000 (the “Adar Note”). The Adar Note is due July 23, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Adar Note is convertible into shares of our common stock at the election of Adar at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Adar Note within 90 days of the closing date at a premium of 135% of all amounts owed to Adar and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Adar Note more than 180 days after the closing date. The Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $3,438. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $34,384 during the year ended March 31, 2019. 50,000 - Unamortized debt discount (15,616) - Total, net of unamortized discount 34,384 - Power UP Lending Group Convertible Note – October 15, 2018 On October 15, 2018 we entered into a Convertible note with Power UP Lending Group LTD (“Power UP”) pursuant to which we issued a convertible promissory note, dated October 15, 2018 in the principal amount of $128,000 (the “Power UP Note”). The Power UP Note is due October 15, 2019 and bears interest at the rate of 8% per annum. All principal and accrued interest on the Power UP Note is convertible into shares of our common stock 180 days following October 15, 2018 at a conversion price equal to a 37% discount to the lowest trading or lowest closing bid price for our common stock during the 15-trading day period immediately prior to conversion. We have the right to prepay the Power UP Note within 30 days of the closing date at a premium of 112% of all amounts owed to Power UP and at a premium of 117% if prepaid more than 31 but less than 60 days following the closing date and at a premium of 122% if prepaid more than 61 but less than 90 days following the closing date and at a premium of 127% if prepaid more than 91 but less than 120 days following the closing date and at a premium of 132% if prepaid more than 121 but less than 150 days following the closing date and at a premium of 137% if prepaid more than 151 but less than 180 days following the closing date. We have no right to prepay the Power UP Note more than 180 days after the closing date. The Power UP Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $4,685. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $58,819 during the year ended March 31, 2019. 128,000 - Unamortized debt discount (69,181) - Total, net of unamortized discount 58,819 - Power UP Lending Group Convertible Note – November 6, 2018 On October 15, 2018 we entered into a Convertible note with Power UP Lending Group LTD (“Power UP”) pursuant to which we issued a convertible promissory note, dated October 15, 2018, in the principal amount of $53,000 (the “Power UP Note-2”). The Power UP Note-2 is due November 6, 2019 and bears interest at the rate of 8% per annum. All principal and accrued interest on the Power UP Note-2 is convertible into shares of our common stock 180 days following October 15, 2018 at a conversion price equal to a 39% discount to the lowest trading or lowest closing bid price for our common stock during the 15-trading day period immediately prior to conversion. We have the right to prepay the Power UP Note within 30 days of the closing date at a premium of 112% of all amounts owed to Power UP and at a premium of 117% if prepaid more than 31 but less than 60 days following the closing date and at a premium of 122% if prepaid more than 61 but less than 90 days following the closing date and at a premium of 127% if prepaid more than 91 but less than 120 days following the closing date and at a premium of 132% if prepaid more than 121 but less than 150 days following the closing date and at a premium of 137% if prepaid more than 151 but less than 180 days following the closing date. We have no right to prepay the Power UP Note more than 180 days after the closing date. The Power UP Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $1,684. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $30,137 during the year ended March 31, 2019. 53,000 - Unamortized debt discount (30,137) - Total, net of unamortized discount 22,863 - Adar Bays, LLC July 2, 2018 Secured Convertible Note- Back end note On July 2, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 2, 2018, in the principal amount of $150,000 (the “July 2, 2018 Adar Back end Note”). On off-setting note was issued by the lender on July 2, 2018, which was released upon funding the July 2, 2018 Adar Back Note on March 2, 2019. The July 2, 2018 Adar Back Note is due July 2, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the July 2, 2018 Adar Note is convertible into shares of our common stock at the election of Adar six months after the issuance date at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We can pay the note in cash within the first six months of issuance, we have no right to prepay the July 2, 2018 Adar Note six months and one day after issuance. The July 2, 2018 Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $941. As of March 31, 2019, the note holder had converted $57,807 in Principal into 51,813,209 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $57,807 during the year ended March 31, 2019. 92,193 - Unamortized debt discount (92,183) - Total, net of unamortized discount - - Adar Bays, LLC July 23, 2018 Secured Convertible Note – Back End Note On July 23, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 23, 2018, in the principal amount of $50,000 (the “July 23, 2018 Adar Back End Note”). On off-setting note was issued by the lender on July 2, 2018, which was released upon funding the July 23, 2018 Adar Back Note on March 20, 2019. The July 23, 2018 Adar Back End Note is due July 23, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Adar Note is convertible into shares of our common stock at the election of Adar at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Adar Note within 90 days of the closing date at a premium of 135% of all amounts owed to Adar and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Adar Note more than 180 days after the closing date. The Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $151. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,507 during the year ended March 31, 2019. 50,000 - Unamortized debt discount (48,493) - Total, net of unamortized discount 1,507 - Eagle Equities, LLC Convertible Note – Back End Note On July 20, 2018 we entered into a Convertible note with Eagle Equities, LLC (“Eagle”) pursuant to which we issued a convertible promissory note, dated July 20, 2018, in the principal amount of $100,000 (the “Eagle Back End Note”). On off-setting note was issued by the lender on July 20, 2018, which was released upon funding the July 20, 2018 Eagle Back End Note on March 20, 2019. The Eagle Back End Note is due July 20, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Eagle Note is convertible into shares of our common stock at the election of Eagle at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Eagle Note within 90 days of the closing date at a premium of 135% of all amounts owed to GS and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Eagle Note more than 180 days after the closing date. The Eagle Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $240. As of March 31, 2019, the note holder had converted $30,000 in Principal and $29 in interest and fees into 33,072,177 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $30,000 during the year ended March 31, 2019. 70,000 - Unamortized debt discount (70,000) - Total, net of unamortized discount - - Total $ 274,688 32,607

Fair Value of Financial Instrum

Fair Value of Financial Instruments and Derivative Liabilities	12 Months Ended
	Mar. 31, 2019
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]
Fair Value of Financial Instruments and Derivative Liabilities	8. FAIR VALUE OF FINANCIAL INSTRUMENTS AND DERIVATIVE LIABILITIES The carrying value of cash, accounts payable and accrued expenses, and debt (See Note 7) approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s long-term debt is also stated at fair value of $2,000,000 since the stated rate of interest approximates market rates. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable. ● Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. ● Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily-available pricing sources for comparable instruments. ● Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The following table presents the derivative financial instruments, the Company’s only financial liabilities measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of March 31, 2019: Amount Level 1 Level 2 Level 3 Embedded conversion derivative liability $ — $ — $ — $ 1,227,041 Warrant and option derivative liabilities $ — $ — $ — $ — Total $ — $ — $ — $ 1,227,041 The embedded conversion feature in the convertible debt instruments that the Company issued (See Note 7), was convertible at issuance which qualified them as a derivative instrument since the number of shares issuable under the note is indeterminate based on guidance in ASC Topic No. 815-15, “Derivatives and Hedging (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. This convertible debt tainted all other equity linked instruments including all outstanding non-employee options and warrants on the date that the instrument became convertible. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note through March 31, 2018 which was the date the derivative liability was terminated: Fair value assumptions: February 23, 2018 through March 31, 2019 Risk free interest rate 2.02-2.72% Expected term (years) 0.01-1 Expected volatility 170.90%-249.85% Expected dividends 0% The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of March 31, 2019: Amount Balance March 31, 2017 $ — Debt discount originated from derivative liabilities 262,500 Initial loss recorded 170,924 Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities 296,313 Balance March 31, 2018 $ 729,737 Debt discount originated from derivative liabilities 824,050 Initial loss recorded 755,733 Adjustment to derivative liability due to debt settlement (1,791,931) Change in fair market value of derivative liabilities 709,452 Balance March 31, 2019 $ 1,227,041

Loans Payable

Loans Payable	12 Months Ended
	Mar. 31, 2019
Receivables [Abstract]
LOANS PAYABLE	9. LOANS PAYABLE On January 8, 2018, the Company and four lenders assigned the rights and obligations of a total of $174,500 in promissory notes to a new lender. All the notes now bear interest at a rate of 5% per annum and are due within two business days of demand notice all other terms we unchanged. During the year ended March 31, 2019 the Company recorded interest of $10,655.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
STOCKHOLDERS' EQUITY	10. STOCKHOLDERS’ EQUITY Overview On January 28, 2018, the Company filed a certificate of amendment (the “Amendment”) with the Nevada Secretary of State to increase the Company’s authorized common stock, par value $0.001 per share, from 1,125,000,000 shares to 4,000,000,000 shares. The Amendment also created a class of 10,000,000 shares of blank check preferred stock, par value $0.001 per share. On January 28, 2019, pursuant to Article III of our Articles of Incorporation, our Board of Directors voted to designate a class of preferred stock entitled Series A Preferred Stock, consisting of up 3,000,000 shares, par value $0.001. Under the Certificate of Designation, holders of Series A Preferred Stock will participate on an equal basis per-share with holders of our common stock in any distribution upon winding up, dissolution, or liquidation. Holders of Series A Preferred Stock are entitled to vote together with the holders of our common stock on all matters submitted to shareholders at a rate of 1,000 votes for each share held. Holders of Series A Preferred Stock are entitled to convert each share held for 10 shares of common stock. As of March 31, 2019, the Company is authorized to issue 4,000,000,000 shares of $0.001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. As of March 31, 2019, there were 597,064,715 shares of common stock issued and outstanding. As of March 31, 2019, there were 3,000,000 shares of Preferred stock issued and outstanding. Issuance of Preferred stock On January 28, 2019, we issued to Mr. Gert Andersen 3,000,000 shares of our newly created Series A Preferred Stock in exchange for 30,000,000 shares of common stock held by Mr. Andersen. Termination of Stock purchase agreement – November 8, 2018 As previously disclosed, on April 19, 2017, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Pharma GP APS, a Denmark corporation (“Pharma GP”) and its sole shareholder, 9 Heroes APS, a Denmark corporation, pursuant to which we agreed to purchase all of the outstanding shares of Pharma GP for the purchase price of $6,000,000.00, payable as $3,000,000.00 in cash and the balance in shares of our common stock. The closing of the Purchase Agreement was originally scheduled to occur on May 31, 2017; however, we have been unable to raise money needed to pay the purchase price under the Purchase Agreement; As a result of the difficulties in raising capital to finance the Purchase Agreement transaction, the parties have decided to terminate and release each other and otherwise settle, compromise, dispose of, and release with finality, all claims, demands and causes of action, arising out of the Purchase Agreement dated April 19, 2017. As such, on November 8, 2019, the parties entered into a Termination and Release Agreement (the “Termination Agreement”) to terminate the Purchase Agreement and release each other from the obligations under the Purchase Agreement. Stock issued for services. On December 3, 2018, the Company issued a total of 1,500,000 shares of the Company’s common stock to a consultant for services to be rendered over 12 months. The shares were valued at $0.115 per share or $172,500. The Company will record the expense evenly over the 12 month service period. During the year ended March 31, 2019 the Company recorded $69,000 as professional fees expense. On December 11, 2018, the Company issued a total of 6,000,000 shares of the Company’s common stock to three directors of the Company for services rendered. The shares were evenly distributed and as a result each director received 2,000,000 shares. The shares were valued at $0.0525 per share or $315,000 which was recorded as professional fees expense. On March 20, 2019, the Company issued a total of 40,909,089 shares of the Company’s common stock to three directors of the Company for services rendered. The shares were evenly distributed and as a result each director received 13,636,363 shares. The shares were valued at $0.0022 per share or $90,000 which was recorded as professional fees expense. VILACTO BIO INC. NOTES TO THE FINANCIAL STATEMENTS MARCH 31, 2019 (AUDITED) Stock issued upon conversion of debts. The following table presents a summary of the Company’s debt conversions associated with its convertible notes during the year ended March 31, 2019: Date of conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 11/20/2018 0.0300 5,996 200,000 11/23/2018 0.0600 6,000 100,000 11/26/2018 0.0455 6,370 140,000 12/4/2018 0.0182 10,920 600,000 12/7/2018 0.0132 33,100 2,500,000 12/11/2018 0.0331 13,240 400,000 12/20/2018 0.0145 7,250 500,000 1/4/2019 0.0030 7,500 2,500,000 1/7/2019 0.0060 4,800 800,000 1/10/2019 0.0075 15,000 2,000,000 1/18/2019 0.0060 4,800 800,000 1/23/2019 0.0075 21,063 2,808,401 1/24/2019 0.0075 15,771 2,102,777 1/29/2019 0.0053 6,384 1,200,000 1/29/2019 0.0043 10,675 2,500,000 1/30/2019 0.0045 15,000 3,333,333 2/6/2019 0.0014 2,880 2,000,000 2/6/2019 0.0018 7,385 4,102,778 2/6/2019 0.0013 8,288 6,400,000 2/7/2019 0.0018 11,540 6,411,111 2/7/2019 0.0018 5,699 3,165,833 2/8/2019 0.0018 11,366 6,314,194 2/11/2019 0.0018 8,026 4,458,889 2/12/2019 0.0014 5,760 4,000,000 2/12/2019 0.0013 9,639 7,650,000 2/13/2019 0.0018 14,491 8,050,556 2/13/2019 0.0018 9,513 5,284,722 2/14/2019 0.0018 15,573 8,651,667 2/19/2019 0.0018 14,817 8,231,667 2/19/2019 0.0014 9,216 6,400,000 2/19/2019 0.0018 10,586 5,881,172 2/21/2019 0.0018 15,557 8,642,778 2/21/2019 0.0014 14,137 10,116,215 2/21/2019 0.0013 10,836 8,600,000 2/26/2019 0.0015 11,953 8,243,268 2/27/2019 0.0011 6,480 6,000,000 2/27/2019 0.0014 10,608 7,577,379 2/28/2019 0.0008 8,131 10,100,000 3/4/2019 0.0012 13,809 12,007,730 3/5/2019 0.0012 14,046 12,213,852 3/5/2019 0.0008 9,821 12,200,000 3/5/2019 0.0012 13,837 12,032,165 3/6/2019 0.0009 12,880 14,000,000 3/6/2019 0.0011 13,816 12,014,009 3/8/2019 0.0007 10,000 15,231,130 3/8/2019 0.0011 10,633 9,246,374 3/11/2019 0.0008 13,765 17,100,000 3/13/2019 0.0006 1,813 2,931,643 3/13/2019 0.0012 8,092 7,036,426 3/14/2019 0.0012 15,000 13,043,478 3/18/2019 0.0009 17,620 19,152,700 3/18/2019 0.0011 20,258 17,630,730 3/19/2019 0.0008 16,100 20,000,000 3/20/2019 0.0012 24,136 20,987,826 3/20/2019 0.0011 15,000 14,285,714 3/22/2019 0.0008 16,088 19,152,700 3/25/2019 0.0011 19,258 18,340,504 3/26/2019 0.0010 18,671 17,781,905 3/26/2019 0.0007 18,375 25,000,000 3/27/2019 — 15,029 — Total $ 724,396 480,155,626 18,786,463 shares of common stock were not yet issued on March 27, 2019 conversion. The converted amount is thus included in stock payable at March 31, 2019.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS In connection with an assumption of the debt agreement the Company executed a $32,608 promissory note with Mr. Anderson which bears interest at a rate of 10% per annum. During the year ended March 31, 2019 the Company recorded interest of $3,261. During the year ended March 31, 2019, Gert Anderson, the President and CEO of the Company advanced $17,740 to the Company to pay expenses on behalf of the Company. As of March 31, 2019, $68,106 in advances remain outstanding. The advances bear no interest, are unsecured, and are due on demand. On July 16, 2018 the Company made a payment of $133,284 to Pharma GP, an entity controlled by our CEO to settle amounts owned under outstanding accounts payable.

Royalty Agreement

Royalty Agreement	12 Months Ended
	Mar. 31, 2019
Research and Development [Abstract]
ROYALTY AGREEMENT	12. ROYALTY AGREEMENT License agreement On April 4, 2017, we entered into a license agreement (the “License Agreement”) with Pharma GP APS, a Company controlled by our CEO. (“Pharma GP”) and acquired an exclusive license to sell certain cosmetic products or ingredients covered by United States Patent No. US 8,637,075 in the territory of the United States. For the license, we agreed to pay to GP a royalty of eight percent (8%) on the selling price (irrespective of any taxes, custom duties, costs of insurance, transportation costs or other costs) for all licensed product we sell in the United States (if in excess of the agreed minimum royalty) or pay the agreed minimum royalty of $10,000 per month. During the year ended March 31, 2019, the Company recorded royalty expense of $80,000 related to this agreement. Under the License Agreement, we have the ability to sublicense to third parties under the royalty arrangement described above. On November 8, 2018, the Royalty agreement was cancelled as a result of the assets purchase described in Note 6. (See note 6 for additional details.)

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
INCOME TAXES	13. INCOME TAXES Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes as of March 31, 2019 and 2018 are as follows: March 31, 2019 2018 Deferred tax assets: Net operating loss tax basis $ 1,077,790 $ 107,332 Provisions and accrued liabilities — — Deferred tax liabilities: Total deferred tax asset 1,077,790 107,332 Less valuation allowance (1,077,790 ) (107,332) Net deferred tax asset $ — $ — As of March 31, 2019, and 2018, the Company had gross federal net operating loss carryforwards of approximately $1,077,790 and $107,332, respectively. The Company expects the limitation placed on the federal net operating loss carryforwards prior to the ownership change will likely expire unused. As of March 31, 2019, all tax years are open for examination by the taxing authorities. Due to the enactment of the Tax Reform Act of 2017, the corporate tax rate for those tax years beginning with 2018 has been reduced to 21%.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet through the issuance date of these financial statements in accordance with FASB ASC 855 and has determined that there are no such events that would require adjustment to, or disclosure in, the financial statements except as disclosed below. Stock issued upon conversion of debts. The following table presents a summary of the Company’s debt conversions associated with its convertible notes between April 1, 2019 and June 4, 2019: Date of Conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 4/1/2019 0.00070 19,366 29,793,253 4/1/2019 0.00050 15,493 29,793,500 4/1/2019 0.00070 19,292 29,680,076 4/2/2019 0.00050 13,423 29,500,000 4/8/2019 0.00060 22,860 35,169,231 4/10/2019 0.00060 10,891 16,755,385 4/10/2019 0.00050 15,925 35,000,000 4/22/2019 0.00100 25,000 25,000,000 4/22/2019 0.00100 25,000 25,000,000 4/23/2019 0.00110 25,000 22,727,273 4/24/2019 0.00100 25,000 26,315,789 4/25/2019 0.00050 19,793 43,500,000 4/26/2019 0.00080 15,000 18,292,683 4/29/2019 0.00050 16,249 30,687,785 4/29/2019 0.00060 13,000 22,087,561 5/1/2019 0.00050 14,400 30,000,000 5/2/2019 0.00040 17,150 49,000,000 5/6/2019 0.00030 17,315 54,110,000 5/8/2019 0.00020 12,985 53,000,000 5/13/2019 0.00020 14,269 59,454,800 5/16/2019 0.00020 10,474 65,465,500 5/20/2019 0.00020 10,600 44,166,667 5/20/2019 0.00020 10,600 44,166,667 5/21/2019 0.00020 10,600 44,166,667 5/22/2019 0.00010 7,245 69,000,000 5/22/2019 0.00020 7,900 43,888,889 5/23/2019 0.00020 8,000 44,444,444 5/28/2019 0.00020 13,311 83,194,900 5/28/2019 0.00020 7,420 41,222,222 5/31/2019 0.00010 7,152 89,403,250 6/4/2019 0.00010 2,336 33,376,857 Total 453,049 1,267,363,399

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2019
Summary Of Significant Accounting Policies Policies
Use of Estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Revenue Recognition	Revenue Recognition In situations where arrangements include customer acceptance provisions based on seller or customer-specified objective criteria, we recognize revenue when we have concluded that the customer has control of the goods and that acceptance is likely to occur. We generally do not provide for anticipated losses on point in time transactions prior to transferring control of the equipment to the customer. For the years ended March 31, 2019 and 2018 the Company reported revenues of $4,894 and $1,429 respectively, respectively.
Accounts Receivable	Accounts Receivable
Cash and Cash Equivalents	Cash and cash equivalents
Concentration Risk	Concentration Risk At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of March 31, 2019, the cash balance in excess of the FDIC limits was $4,871. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The three levels of the fair value hierarchy are described below: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
Stock Based Compensation	Stock-based compensation Compensation-Stock Compensation,
Non-Employee Stock Based Compensation	Non-Employee Stock Based Compensation
Earnings per Share	Earnings (loss) per share Earnings Per Share,
Long Lived Assets	Long-lived Assets
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms in agreements are reviewed to determine whether or not they contain embedded derivatives that are required under ASC 815 to be accounted for and separated from the host contract, and recorded on the balance sheet at fair value. The fair value of derivative liabilities is required to be revalued at each reporting date, with the corresponding changes in fair value recorded in current period operating results.
Inventory	Inventory
Income Taxes	Income taxes Income Taxes
Segment Reporting	Segment Reporting
Recent Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, “Leases” (“ASC 842”). The guidance requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model and the new revenue recognition standard. Existing sale-leaseback guidance, including guidance for real estate, is replaced with a new model applicable to both lessees and lessors. ASC 842 is effective for fiscal years beginning after December 15, 2018. We will plan to adopt ASC 842 effective April 1, 2019 using the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on April 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under the prior lease accounting guidance in ASC 840. We plan to elect the transition relief package of practical expedients, and as a result, we will not assess 1) whether existing or expired contracts contain embedded leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We will also elect the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventory	March 31, 2019 March 31, 2018 Raw materials $ — $ — Finished Goods 119,045 100,413 Total $ 119,045 $ 100,413

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Mar. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses	March 31, 2019 March 31, 2018 Prepaid Marketing $ — $ 59,568 Total prepaid expenses $ — $ 59,568

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	March 31, 2019 March 31, 2018 Patents and trademarks $ 135,850 $ 920 Website 21,394 — Less: accumulated amortization (7,164 ) (24) Intangible assets, net of accumulated amortization $ 150,080 $ 896

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	Convertible Notes Payable at consists of the following: March 31, March 31, 2019 2018 Auctus Fund, LLC On February 26, 2018, we entered into a Securities Purchase Agreement (the “Auctus SPA”), under which we agreed to sell a 12% convertible promissory note in an aggregate principal amount of $167,750 (the “Auctus Note”) to Auctus Fund, LLC (“Auctus”). The Auctus Note bears interest at a rate of 12% per annum and matured on November 26, 2018. The net proceeds of the sale of the Auctus Note, after deducting the expenses payable, were $150,000. At any time after the issue date of the Auctus Note, Auctus has the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Auctus Note into shares of our common stock at the Conversion Price. The “Conversion Price” is the lesser of (i) the lowest trading price of our common stock during the twenty-five-day trading period prior to the issue date of the Auctus Note and (ii) 50% of the lowest trading price of our common stock during the twenty-five-day trading period prior to the conversion. The Conversion Price is subject to further reduction upon certain events specified in the Auctus Note. We have the right to prepay the Auctus Note at any time until the 180th calendar day after the issue date of the Auctus Note, in an amount equal to 150% (or 135% if we prepay the Auctus Note on or before the date that is 90 days after the issue date of the Auctus Note) of the outstanding balance of the Auctus Note (including principal and accrued and unpaid interest). We may not prepay the Auctus Note after the 180th calendar day after the issue date of the Auctus Note. We will be subject to a liquidated damages charge of 25% of the outstanding principal amount of the Auctus Note if we effect certain exchange transactions in accordance with, based upon or related or pursuant to Section 3(a)(10) of the Securities Act. In addition, the Auctus Note grants Auctus the right to update the terms of the Auctus SPA and the Auctus Note to incorporate the terms of any future transaction document related to a security issuance by us to a third party that are more favorable to the third party than the terms of the Auctus SPA and the Auctus Note. Any amounts due and payable to Auctus under the terms of the Auctus Note, including any payment on an event of default, default interest, or agreed upon liquidated damages may, at the Auctus's option, be converted into shares of our common stock at the Conversion Price. Pursuant to a Registration Rights Agreement, we are required to register 30,000,000 shares into which the Auctus Note may be converted. As of March 31, 2019 the note holder had converted $87,352 in Principal and $25,417 in interest and fees into 74,645,400 shares of the Company’s common stock. (See note 9 for additional details.) During the year ended March 31, 2019 the Company recorded interest of $23,597. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $147,472 during the year ended March 31, 2019. $ 80,398 167,750 Unamortized debt discount - (147,472) Total, net of unamortized discount 80,398 20,278 EMA Financial, LLC On February 23, 2018 we entered into a Securities Purchase Agreement (“EMA SPA”) with EMA Financial, LLC, a Delaware limited liability company (“EMA”), pursuant to which we issued and sold to EMA a convertible promissory note, dated February 23, 2018 in the principal amount of $125,000 (the “EMA Note”). In connection with the foregoing, we also entered into a Registration Rights Agreement with the Purchaser dated February 23, 2018 (the “Registration Rights Agreement”). The EMA Note, as amended, was due February 23, 2019 and bears interest at the rate of 12% per annum. All principal and accrued interest on the EMA Note is convertible into shares of our common stock at the election of EMA at any time at a conversion price equal to the lesser of (i) the trading price for our common stock on the trading day prior to the closing date of the EMA Note, or (ii) a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have no right to prepay the EMA Note more than 180 days after the closing date. The EMA Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. As a result of claimed defaults, the promissory notes discount conversion rate was increased to a 80% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion On July 6, 2018, the Company executed an amendment to the promissory note to cure certain events of default in which it agreed to increase the principal balance of the note by $37,500 and pay $25,000 in principal to the lender within 5 days of execution of the amendment. The company treated the amendment as a debt modification under ASC 470 and recorded a corresponding loss on debt modification of $37,500. During the year ended March 31, 2019 the Company incurred additional penalties of approximately $120,533 which were added to the principal total owed under the promissory note. As of March 31, 2019, the note holder had converted $146,316 in Principal and $16,830 in interest and fees into 115,350,000 shares of the Company’s common stock. (See note 9 for additional details.) During the year ended March 31, 2019 the Company recorded interest of $13,614. In July 2018, the Company made a cash payment of principal and interest of $60,000 on the then outstanding balance. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $150,171 during the year ended March 31, 2019. 76,717 125,000 Unamortized debt discount - (112,671) Total, net of unamortized discount 76,717 12,329 Adar Bays, LLC July 2, 2018 Secured Convertible Note On July 2, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 2, 2018 in the principal amount of $150,000 (the “July 2, 2018 Adar Note”). The July 2, 2018 Adar Note is due July 2, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the July 2, 2018 Adar Note is convertible into shares of our common stock at the election of Adar six months after the issuance date at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We can pay the note in cash within the first six months of issuance, we have no right to prepay the July 2, 2018 Adar Note six months and one day after issuance. The July 2, 2018 Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $9,314. As of March 31, 2019, the note holder had converted $150,000 in Principal into 90,272,841 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $150,000 during the year ended March 31, 2019. - - Unamortized debt discount - - Total, net of unamortized discount - - GS Capital Partners, LLC Convertible Note On July 11, 2018 we entered into a Convertible note with GS Capital Bays, LLC (“GS”) pursuant to which we issued a convertible promissory note, dated July 11, 2018 in the principal amount of $110,000 (the “GS Note”). The GS Note is due July 11, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the GS Note is convertible into shares of our common stock at the election of GS at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the GS Note within 60 days of the closing date at a premium of 125% of all amounts owed to GS and at a premium of 135% if prepaid more than 60 but less than 120 days following the closing date, at a premium of 145% if prepaid more than 120 but less than 180 days following the closing date. We have no right to prepay the GS Note more than 180 days after the closing date. The GS Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $7,113 As of March 31, 2019, the note holder had converted $92,000 in Principal and $5,733 in interest and fees into 65,369,262 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $92,000 during the year ended March 31, 2019. 18,000 - Unamortized debt discount (18,000) - Total, net of unamortized discount - - Eagle Equities, LLC Convertible Note On July 20, 2018 we entered into a Convertible note with Eagle Equities, LLC (“Eagle”) pursuant to which we issued a convertible promissory note, dated July 20, 2018 in the principal amount of $100,000 (the “Eagle Note”). The Eagle Note is due July 20, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Eagle Note is convertible into shares of our common stock at the election of Eagle at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Eagle Note within 90 days of the closing date at a premium of 135% of all amounts owed to GS and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Eagle Note more than 180 days after the closing date. The Eagle Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $5,913. As of March 31, 2019, the note holder had converted $100,000 in Principal and $5,911 in interest and fees into 68,419,200 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $100,000 during the year ended March 31, 2019. - - Unamortized debt discount - - Total, net of unamortized discount - - Adar Bays, LLC July 23, 2018 Secured Convertible Note On July 23, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 23, 2018, in the principal amount of $50,000 (the “Adar Note”). The Adar Note is due July 23, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Adar Note is convertible into shares of our common stock at the election of Adar at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Adar Note within 90 days of the closing date at a premium of 135% of all amounts owed to Adar and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Adar Note more than 180 days after the closing date. The Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $3,438. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $34,384 during the year ended March 31, 2019. 50,000 - Unamortized debt discount (15,616) - Total, net of unamortized discount 34.384 - Power UP Lending Group Convertible Note – October 15, 2018 On October 15, 2018 we entered into a Convertible note with Power UP Lending Group LTD (“Power UP”) pursuant to which we issued a convertible promissory note, dated October 15, 2018 in the principal amount of $128,000 (the “Power UP Note”). The Power UP Note is due October 15, 2019 and bears interest at the rate of 8% per annum. All principal and accrued interest on the Power UP Note is convertible into shares of our common stock 180 days following October 15, 2018 at a conversion price equal to a 37% discount to the lowest trading or lowest closing bid price for our common stock during the 15-trading day period immediately prior to conversion. We have the right to prepay the Power UP Note within 30 days of the closing date at a premium of 112% of all amounts owed to Power UP and at a premium of 117% if prepaid more than 31 but less than 60 days following the closing date and at a premium of 122% if prepaid more than 61 but less than 90 days following the closing date and at a premium of 127% if prepaid more than 91 but less than 120 days following the closing date and at a premium of 132% if prepaid more than 121 but less than 150 days following the closing date and at a premium of 137% if prepaid more than 151 but less than 180 days following the closing date. We have no right to prepay the Power UP Note more than 180 days after the closing date. The Power UP Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $4,685. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $58,819 during the year ended March 31, 2019. 128,000 - Unamortized debt discount (69,181) - Total, net of unamortized discount 58,819 - Power UP Lending Group Convertible Note – November 6, 2018 On October 15, 2018 we entered into a Convertible note with Power UP Lending Group LTD (“Power UP”) pursuant to which we issued a convertible promissory note, dated October 15, 2018, in the principal amount of $53,000 (the “Power UP Note-2”). The Power UP Note-2 is due November 6, 2019 and bears interest at the rate of 8% per annum. All principal and accrued interest on the Power UP Note-2 is convertible into shares of our common stock 180 days following October 15, 2018 at a conversion price equal to a 39% discount to the lowest trading or lowest closing bid price for our common stock during the 15-trading day period immediately prior to conversion. We have the right to prepay the Power UP Note within 30 days of the closing date at a premium of 112% of all amounts owed to Power UP and at a premium of 117% if prepaid more than 31 but less than 60 days following the closing date and at a premium of 122% if prepaid more than 61 but less than 90 days following the closing date and at a premium of 127% if prepaid more than 91 but less than 120 days following the closing date and at a premium of 132% if prepaid more than 121 but less than 150 days following the closing date and at a premium of 137% if prepaid more than 151 but less than 180 days following the closing date. We have no right to prepay the Power UP Note more than 180 days after the closing date. The Power UP Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $1,684. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $30,137 during the year ended March 31, 2019. 53,000 - Unamortized debt discount (30,137) - Total, net of unamortized discount 22,863 - Adar Bays, LLC July 2, 2018 Secured Convertible Note- Back end note On July 2, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 2, 2018, in the principal amount of $150,000 (the “July 2, 2018 Adar Back end Note”). On off-setting note was issued by the lender on July 2, 2018, which was released upon funding the July 2, 2018 Adar Back Note on March 2, 2019. The July 2, 2018 Adar Back Note is due July 2, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the July 2, 2018 Adar Note is convertible into shares of our common stock at the election of Adar six months after the issuance date at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We can pay the note in cash within the first six months of issuance, we have no right to prepay the July 2, 2018 Adar Note six months and one day after issuance. The July 2, 2018 Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $941. As of March 31, 2019, the note holder had converted $57,807 in Principal into 51,813,209 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $57,807 during the year ended March 31, 2019. 92,193 - Unamortized debt discount (92,183) - Total, net of unamortized discount - - Adar Bays, LLC July 23, 2018 Secured Convertible Note – Back End Note On July 23, 2018 we entered into a Secured Convertible note with Adar Bays, LLC (“Adar”) pursuant to which we issued a convertible promissory note, dated July 23, 2018, in the principal amount of $50,000 (the “July 23, 2018 Adar Back End Note”). On off-setting note was issued by the lender on July 2, 2018, which was released upon funding the July 23, 2018 Adar Back Note on March 20, 2019. The July 23, 2018 Adar Back End Note is due July 23, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Adar Note is convertible into shares of our common stock at the election of Adar at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Adar Note within 90 days of the closing date at a premium of 135% of all amounts owed to Adar and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Adar Note more than 180 days after the closing date. The Adar Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $151. The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $1,507 during the year ended March 31, 2019. 50,000 - Unamortized debt discount (48,493) - Total, net of unamortized discount 1,507 - Eagle Equities, LLC Convertible Note – Back End Note On July 20, 2018 we entered into a Convertible note with Eagle Equities, LLC (“Eagle”) pursuant to which we issued a convertible promissory note, dated July 20, 2018, in the principal amount of $100,000 (the “Eagle Back End Note”). On off-setting note was issued by the lender on July 20, 2018, which was released upon funding the July 20, 2018 Eagle Back End Note on March 20, 2019. The Eagle Back End Note is due July 20, 2019 and bears interest at the rate of 10% per annum. All principal and accrued interest on the Eagle Note is convertible into shares of our common stock at the election of Eagle at any time at a conversion price equal to a 50% discount to the lowest trading or lowest closing bid price for our common stock during the 25-trading day period immediately prior to conversion. We have the right to prepay the Eagle Note within 90 days of the closing date at a premium of 135% of all amounts owed to GS and at a premium of 150% if prepaid more than 90 but less than 180 days following the closing date. We have no right to prepay the Eagle Note more than 180 days after the closing date. The Eagle Note contains customary default events which, if triggered and not timely cured, will result in default interest and penalties. During the year ended March 31, 2019 the Company recorded interest of $240. As of March 31, 2019, the note holder had converted $30,000 in Principal and $29 in interest and fees into 33,072,177 shares of the Company’s common stock. (See note 9 for additional details.) The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $30,000 during the year ended March 31, 2019. 70,000 - Unamortized debt discount (70,000) - Total, net of unamortized discount - - Total $ 274,688 32,607
Derivative liabilities associated with Convertible Debt	Amount Balance March 31, 2017 $ — Debt discount originated from derivative liabilities 262,500 Initial loss recorded 170,924 Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities 296,313 Balance March 31, 2018 $ 729,737 Debt discount originated from derivative liabilities 824,050 Initial loss recorded 755,733 Adjustment to derivative liability due to debt settlement (1,791,931) Change in fair market value of derivative liabilities 709,452 Balance March 31, 2019 $ 1,227,041
Black-Scholes Model	Fair value assumptions: February 23, 2018 through March 31, 2019 Risk free interest rate 2.02-2.72% Expected term (years) 0.01-1 Expected volatility 170.90%-249.85% Expected dividends 0%

Fair Value of Financial Instr_2

Fair Value of Financial Instruments and Derivative Liabilities (Tables)	12 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Derivative Financial Instruments	Amount Level 1 Level 2 Level 3 Embedded conversion derivative liability $ — $ — $ — $ 1,227,041 Warrant and option derivative liabilities $ — $ — $ — $ — Total $ — $ — $ — $ 1,227,041
Black-Scholes Model	Fair value assumptions: February 23, 2018 through March 31, 2019 Risk free interest rate 2.02-2.72% Expected term (years) 0.01-1 Expected volatility 170.90%-249.85% Expected dividends 0%
Derivative liabilities associated with Convertible Debt	Amount Balance March 31, 2017 $ — Debt discount originated from derivative liabilities 262,500 Initial loss recorded 170,924 Adjustment to derivative liability due to debt settlement — Change in fair market value of derivative liabilities 296,313 Balance March 31, 2018 $ 729,737 Debt discount originated from derivative liabilities 824,050 Initial loss recorded 755,733 Adjustment to derivative liability due to debt settlement (1,791,931) Change in fair market value of derivative liabilities 709,452 Balance March 31, 2019 $ 1,227,041

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	2 Months Ended	12 Months Ended
	Jun. 04, 2019	Mar. 31, 2019
Equity [Abstract]
Debt Conversion	Date of Conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 4/1/2019 0.00070 19,366 29,793,253 4/1/2019 0.00050 15,493 29,793,500 4/1/2019 0.00070 19,292 29,680,076 4/2/2019 0.00050 13,423 29,500,000 4/8/2019 0.00060 22,860 35,169,231 4/10/2019 0.00060 10,891 16,755,385 4/10/2019 0.00050 15,925 35,000,000 4/22/2019 0.00100 25,000 25,000,000 4/22/2019 0.00100 25,000 25,000,000 4/23/2019 0.00110 25,000 22,727,273 4/24/2019 0.00100 25,000 26,315,789 4/25/2019 0.00050 19,793 43,500,000 4/26/2019 0.00080 15,000 18,292,683 4/29/2019 0.00050 16,249 30,687,785 4/29/2019 0.00060 13,000 22,087,561 5/1/2019 0.00050 14,400 30,000,000 5/2/2019 0.00040 17,150 49,000,000 5/6/2019 0.00030 17,315 54,110,000 5/8/2019 0.00020 12,985 53,000,000 5/13/2019 0.00020 14,269 59,454,800 5/16/2019 0.00020 10,474 65,465,500 5/20/2019 0.00020 10,600 44,166,667 5/20/2019 0.00020 10,600 44,166,667 5/21/2019 0.00020 10,600 44,166,667 5/22/2019 0.00010 7,245 69,000,000 5/22/2019 0.00020 7,900 43,888,889 5/23/2019 0.00020 8,000 44,444,444 5/28/2019 0.00020 13,311 83,194,900 5/28/2019 0.00020 7,420 41,222,222 5/31/2019 0.00010 7,152 89,403,250 6/4/2019 0.00010 2,336 33,376,857 Total 453,049 1,267,363,399	Date of conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 11/20/2018 0.0300 5,996 200,000 11/23/2018 0.0600 6,000 100,000 11/26/2018 0.0455 6,370 140,000 12/4/2018 0.0182 10,920 600,000 12/7/2018 0.0132 33,100 2,500,000 12/11/2018 0.0331 13,240 400,000 12/20/2018 0.0145 7,250 500,000 1/4/2019 0.0030 7,500 2,500,000 1/7/2019 0.0060 4,800 800,000 1/10/2019 0.0075 15,000 2,000,000 1/18/2019 0.0060 4,800 800,000 1/23/2019 0.0075 21,063 2,808,401 1/24/2019 0.0075 15,771 2,102,777 1/29/2019 0.0053 6,384 1,200,000 1/29/2019 0.0043 10,675 2,500,000 1/30/2019 0.0045 15,000 3,333,333 2/6/2019 0.0014 2,880 2,000,000 2/6/2019 0.0018 7,385 4,102,778 2/6/2019 0.0013 8,288 6,400,000 2/7/2019 0.0018 11,540 6,411,111 2/7/2019 0.0018 5,699 3,165,833 2/8/2019 0.0018 11,366 6,314,194 2/11/2019 0.0018 8,026 4,458,889 2/12/2019 0.0014 5,760 4,000,000 2/12/2019 0.0013 9,639 7,650,000 2/13/2019 0.0018 14,491 8,050,556 2/13/2019 0.0018 9,513 5,284,722 2/14/2019 0.0018 15,573 8,651,667 2/19/2019 0.0018 14,817 8,231,667 2/19/2019 0.0014 9,216 6,400,000 2/19/2019 0.0018 10,586 5,881,172 2/21/2019 0.0018 15,557 8,642,778 2/21/2019 0.0014 14,137 10,116,215 2/21/2019 0.0013 10,836 8,600,000 2/26/2019 0.0015 11,953 8,243,268 2/27/2019 0.0011 6,480 6,000,000 2/27/2019 0.0014 10,608 7,577,379 2/28/2019 0.0008 8,131 10,100,000 3/4/2019 0.0012 13,809 12,007,730 3/5/2019 0.0012 14,046 12,213,852 3/5/2019 0.0008 9,821 12,200,000 3/5/2019 0.0012 13,837 12,032,165 3/6/2019 0.0009 12,880 14,000,000 3/6/2019 0.0011 13,816 12,014,009 3/8/2019 0.0007 10,000 15,231,130 3/8/2019 0.0011 10,633 9,246,374 3/11/2019 0.0008 13,765 17,100,000 3/13/2019 0.0006 1,813 2,931,643 3/13/2019 0.0012 8,092 7,036,426 3/14/2019 0.0012 15,000 13,043,478 3/18/2019 0.0009 17,620 19,152,700 3/18/2019 0.0011 20,258 17,630,730 3/19/2019 0.0008 16,100 20,000,000 3/20/2019 0.0012 24,136 20,987,826 3/20/2019 0.0011 15,000 14,285,714 3/22/2019 0.0008 16,088 19,152,700 3/25/2019 0.0011 19,258 18,340,504 3/26/2019 0.0010 18,671 17,781,905 3/26/2019 0.0007 18,375 25,000,000 3/27/2019 — 15,029 — Total $ 724,396 480,155,626

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2019
Income Taxes Tables
Summary of deferred tax assets	March 31, 2019 2018 Deferred tax assets: Net operating loss tax basis $ 1,077,790 $ 107,332 Provisions and accrued liabilities — — Deferred tax liabilities: Total deferred tax asset 1,077,790 107,332 Less valuation allowance (1,077,790 ) (107,332) Net deferred tax asset $ — $ —

Subsequent Events (Tables)

Subsequent Events (Tables)	2 Months Ended	12 Months Ended
	Jun. 04, 2019	Mar. 31, 2019
Subsequent Events [Abstract]
Debt Conversion	Date of Conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 4/1/2019 0.00070 19,366 29,793,253 4/1/2019 0.00050 15,493 29,793,500 4/1/2019 0.00070 19,292 29,680,076 4/2/2019 0.00050 13,423 29,500,000 4/8/2019 0.00060 22,860 35,169,231 4/10/2019 0.00060 10,891 16,755,385 4/10/2019 0.00050 15,925 35,000,000 4/22/2019 0.00100 25,000 25,000,000 4/22/2019 0.00100 25,000 25,000,000 4/23/2019 0.00110 25,000 22,727,273 4/24/2019 0.00100 25,000 26,315,789 4/25/2019 0.00050 19,793 43,500,000 4/26/2019 0.00080 15,000 18,292,683 4/29/2019 0.00050 16,249 30,687,785 4/29/2019 0.00060 13,000 22,087,561 5/1/2019 0.00050 14,400 30,000,000 5/2/2019 0.00040 17,150 49,000,000 5/6/2019 0.00030 17,315 54,110,000 5/8/2019 0.00020 12,985 53,000,000 5/13/2019 0.00020 14,269 59,454,800 5/16/2019 0.00020 10,474 65,465,500 5/20/2019 0.00020 10,600 44,166,667 5/20/2019 0.00020 10,600 44,166,667 5/21/2019 0.00020 10,600 44,166,667 5/22/2019 0.00010 7,245 69,000,000 5/22/2019 0.00020 7,900 43,888,889 5/23/2019 0.00020 8,000 44,444,444 5/28/2019 0.00020 13,311 83,194,900 5/28/2019 0.00020 7,420 41,222,222 5/31/2019 0.00010 7,152 89,403,250 6/4/2019 0.00010 2,336 33,376,857 Total 453,049 1,267,363,399	Date of conversion Effective conversion price Principal and interest converted Shares issued upon conversion of debts 11/20/2018 0.0300 5,996 200,000 11/23/2018 0.0600 6,000 100,000 11/26/2018 0.0455 6,370 140,000 12/4/2018 0.0182 10,920 600,000 12/7/2018 0.0132 33,100 2,500,000 12/11/2018 0.0331 13,240 400,000 12/20/2018 0.0145 7,250 500,000 1/4/2019 0.0030 7,500 2,500,000 1/7/2019 0.0060 4,800 800,000 1/10/2019 0.0075 15,000 2,000,000 1/18/2019 0.0060 4,800 800,000 1/23/2019 0.0075 21,063 2,808,401 1/24/2019 0.0075 15,771 2,102,777 1/29/2019 0.0053 6,384 1,200,000 1/29/2019 0.0043 10,675 2,500,000 1/30/2019 0.0045 15,000 3,333,333 2/6/2019 0.0014 2,880 2,000,000 2/6/2019 0.0018 7,385 4,102,778 2/6/2019 0.0013 8,288 6,400,000 2/7/2019 0.0018 11,540 6,411,111 2/7/2019 0.0018 5,699 3,165,833 2/8/2019 0.0018 11,366 6,314,194 2/11/2019 0.0018 8,026 4,458,889 2/12/2019 0.0014 5,760 4,000,000 2/12/2019 0.0013 9,639 7,650,000 2/13/2019 0.0018 14,491 8,050,556 2/13/2019 0.0018 9,513 5,284,722 2/14/2019 0.0018 15,573 8,651,667 2/19/2019 0.0018 14,817 8,231,667 2/19/2019 0.0014 9,216 6,400,000 2/19/2019 0.0018 10,586 5,881,172 2/21/2019 0.0018 15,557 8,642,778 2/21/2019 0.0014 14,137 10,116,215 2/21/2019 0.0013 10,836 8,600,000 2/26/2019 0.0015 11,953 8,243,268 2/27/2019 0.0011 6,480 6,000,000 2/27/2019 0.0014 10,608 7,577,379 2/28/2019 0.0008 8,131 10,100,000 3/4/2019 0.0012 13,809 12,007,730 3/5/2019 0.0012 14,046 12,213,852 3/5/2019 0.0008 9,821 12,200,000 3/5/2019 0.0012 13,837 12,032,165 3/6/2019 0.0009 12,880 14,000,000 3/6/2019 0.0011 13,816 12,014,009 3/8/2019 0.0007 10,000 15,231,130 3/8/2019 0.0011 10,633 9,246,374 3/11/2019 0.0008 13,765 17,100,000 3/13/2019 0.0006 1,813 2,931,643 3/13/2019 0.0012 8,092 7,036,426 3/14/2019 0.0012 15,000 13,043,478 3/18/2019 0.0009 17,620 19,152,700 3/18/2019 0.0011 20,258 17,630,730 3/19/2019 0.0008 16,100 20,000,000 3/20/2019 0.0012 24,136 20,987,826 3/20/2019 0.0011 15,000 14,285,714 3/22/2019 0.0008 16,088 19,152,700 3/25/2019 0.0011 19,258 18,340,504 3/26/2019 0.0010 18,671 17,781,905 3/26/2019 0.0007 18,375 25,000,000 3/27/2019 — 15,029 — Total $ 724,396 480,155,626

Organization and Line Business

Organization and Line Business (Details Narrative)	12 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Date of incorporation	Feb. 25, 2013
Date of license agreement with Pharma GP ApS	Apr. 4, 2017

Basis of Presentation and Goi_2

Basis of Presentation and Going Concern (Details Narrative) - USD ($)	12 Months Ended	73 Months Ended
	Mar. 31, 2018	Mar. 31, 2019
Going Concern Details Narrative
Net loss	$ (893,117)	$ (7,858,045)

Summary of Significant Policies

Summary of Significant Policies (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accounting Policies [Abstract]
Revenues	4894	1429
Allowance for doubfult accounts	$ 23	$ 36
Cash and Cash Equivalents	257,218	$ 148,747
Cash in excess of FDIC limits	$ 4,871
Shares reserved	9,850,000

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials
Finished Goods	119,045	100,413
Total	$ 119,045	$ 100,413

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid fees		$ 59,568
Total prepaid expenses		$ 59,568

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents and Trademarks	$ 135,850	$ 920
Website	$ 21,394
Less: accumulated depreciation		24
Fixed assets, net of accumulated depreciation		$ 896

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Nov. 08, 2018
Amortization Expense	$ 7,164	$ 24
Common stock issued	597,064,715	90,000,000
Loss on assets acquired from related party	$ (3,242,070)
9 Heroes APS member
Purchase price of assets			$ 3,360,000
Secured promissory note			$ 2,000,000
Common stock issued			8,500,000
Secured promissory note, interest rate	8.00%
Loss on assets acquired from related party	$ 3,242,070

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Conversions of Stock (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Total Net of Unamortized Discount	$ 274,688	$ 32,607
Convertible Note 1
Convertible Note Payable	80,398	167,750
Unamortized debt discount		(147,472)
Total Net of Unamortized Discount	80,398	20,278
Convertible Note 2
Convertible Note Payable	76,717	125,000
Unamortized debt discount		(112,671)
Total Net of Unamortized Discount	74,717	12,329
Convertible Note 3
Convertible Note Payable
Unamortized debt discount
Total Net of Unamortized Discount
Convertible Note 4
Convertible Note Payable	18,000
Unamortized debt discount	(18,000)
Total Net of Unamortized Discount
Convertible Note 5
Convertible Note Payable
Unamortized debt discount
Total Net of Unamortized Discount
Convertible Note 6
Convertible Note Payable	50,000
Unamortized debt discount	(15,616)
Total Net of Unamortized Discount	34,384
Convertible Note 7
Convertible Note Payable	128,000
Unamortized debt discount	(69,181)
Total Net of Unamortized Discount	58,819
Convertible Note 8
Convertible Note Payable	53,000
Unamortized debt discount	(30,137)
Total Net of Unamortized Discount	22,863
Convertible Note 9
Convertible Note Payable	92,193
Unamortized debt discount	(92,193)
Total Net of Unamortized Discount
Convertible Note 10
Convertible Note Payable	50,000
Unamortized debt discount	(48,493)
Total Net of Unamortized Discount	1,507
Convertible Note 11
Convertible Note Payable	70,000
Unamortized debt discount	$ (70,000)

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	12 Months Ended
	Mar. 31, 2019USD ($)shares
Convertible Note 1
Execution Date	Feb. 26, 2018
Mayurity Date	Nov. 26, 2018
Net Proceeds	$ 150,000
Financing expense	$ 147,472
Required Shares to Register | shares	30,000,000
Convertible Note 2
Execution Date	Feb. 23, 2018
Mayurity Date	Feb. 23, 2019
Financing expense	$ 150,171
Payment of Note	25,000
Increase Balance of Note	37,500
Loss on debt modification	37,500
Principal and interest payments	$ 60,000
Required Shares to Register | shares	30,000,000
Convertible note penalties	$ 120,533
Convertible Note 3
Execution Date	Jul. 2, 2018
Mayurity Date	Jul. 2, 2019
Financing expense	$ 150,000
Convertible Note 4
Execution Date	Jul. 11, 2018
Mayurity Date	Jul. 11, 2019
Financing expense	$ 92,000
Convertible Note 5
Execution Date	Jul. 20, 2018
Mayurity Date	Jul. 20, 2019
Financing expense	$ 100,000
Convertible Note 6
Execution Date	Jul. 23, 2018
Mayurity Date	Jul. 23, 2019
Financing expense	$ 34,384
Convertible Note 7
Execution Date	Oct. 15, 2018
Mayurity Date	Oct. 15, 2019
Financing expense	$ 58,819
Convertible Note 8
Execution Date	Oct. 15, 2018
Mayurity Date	Oct. 15, 2019
Financing expense	$ 30,137
Convertible Note 9
Execution Date	Jul. 2, 2018
Mayurity Date	Jul. 2, 2019
Financing expense	$ 57,807
Convertible Note 10
Execution Date	Jul. 23, 2018
Mayurity Date	Aug. 23, 2019
Financing expense	$ 1,507
Convertible Note 11
Execution Date	Jul. 20, 2018
Mayurity Date	Jul. 20, 2019
Financing expense	$ 30,000
Convertible Note One
Convertible Notes Payable, Value	$ 167,750
Interest Rate	12.00%
Accrued Interest	$ 23,597
Principal converted	87,352
Interest converted	$ 25,417
Convertible into Shares | shares	74,645,400
Convertible Note Two
Convertible Notes Payable, Value	$ 125,000
Interest Rate	12.00%
Accrued Interest	$ 13,614
Principal converted	146,316
Interest converted	$ 16,830
Convertible into Shares | shares	115,350,000
Convertible Note Three
Convertible Notes Payable, Value	$ 150,000
Interest Rate	10.00%
Accrued Interest	$ 9,314
Principal converted	$ 150,000
Convertible into Shares | shares	90,272,841
Convertible Note Four
Convertible Notes Payable, Value	$ 110,000
Interest Rate	10.00%
Accrued Interest	$ 7,113
Principal converted	92,000
Interest converted	$ 5,733
Convertible into Shares | shares	65,369,262
Convertible Note Five
Convertible Notes Payable, Value	$ 100,000
Interest Rate	10.00%
Accrued Interest	$ 5,913
Principal converted	100,000
Interest converted	$ 5,911
Convertible into Shares | shares	68,419,200
Convertible Note Six
Convertible Notes Payable, Value	$ 50,000
Interest Rate	10.00%
Accrued Interest	$ 3,438
Convertible Note Seven
Convertible Notes Payable, Value	$ 128,000
Interest Rate	8.00%
Accrued Interest	$ 4,685
Convertible Note Eight
Convertible Notes Payable, Value	$ 53,000
Interest Rate	8.00%
Accrued Interest	$ 1,684
Convertible Note Nine
Convertible Notes Payable, Value	$ 150,000
Interest Rate	10.00%
Accrued Interest	$ 941
Principal converted	$ 57,807
Convertible into Shares | shares	51,813,209
Convertible Note Ten
Convertible Notes Payable, Value	$ 50,000
Interest Rate	10.00%
Accrued Interest	$ 151
Convertible Note Eleven
Convertible Notes Payable, Value	$ 100,000
Interest Rate	10.00%
Accrued Interest	$ 240
Principal converted	30,000
Interest converted	$ 29
Convertible into Shares | shares	33,072,177

Fair Value Of Financial Instr_3

Fair Value Of Financial Instruments And Derivative Liabilities - Derivative Financial Instruments (Details)	12 Months Ended
	Mar. 31, 2019USD ($)
Amount
Embedded Conversion Derivative Liability
Warrant and Option Derivative Liabilities
Total
Level 1
Embedded Conversion Derivative Liability
Warrant and Option Derivative Liabilities
Total
Level 2
Embedded Conversion Derivative Liability
Warrant and Option Derivative Liabilities
Total
Level 3
Embedded Conversion Derivative Liability	1,227,041
Warrant and Option Derivative Liabilities
Total	$ 1,227,041

Fair Value Of Financial Instr_4

Fair Value Of Financial Instruments and Derivative Liabilities - Fair Value Assumptions (Details) - USD ($)	13 Months Ended
	Mar. 31, 2019	Feb. 23, 2018
Fair Value Disclosures [Abstract]
Risk free interest rate	2.72%	2.02%
Expected term in years	12 days
Expected term in years maximum	1 year
Expected Volatility	24985.00%	17090.00%
Expected Dividends	$ 0	$ 0

Fair Value Of Financial Instr_5

Fair Value Of Financial Instruments and Derivative Liabilities - Derivative Liabilities (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Debt Discount originated from Derivative Liabilities	$ 824,050	$ 262,500
Initial Loss Recorded	755,733	170,924
Adjustment to Derivative Liability due to debt settlement	(1,791,931)
Change in fair market value	709,452	296,313
Balance	$ 1,227,041	$ 729,737

Fair Value of Financial Instr_6

Fair Value of Financial Instruments and Derivative Liabilities (Details Narrative)	Mar. 31, 2019USD ($)
Fair Value Disclosures [Abstract]
Long term debt carrying amount	$ 2,000,000

Loans Payable (Details Narrativ

Loans Payable (Details Narrative)	12 Months Ended
	Mar. 31, 2019USD ($)	Jan. 08, 2018USD ($)
Promissorry Notes		$ 174,500
Interest Rate of Promissory Note		0.05
Loans Payable [Member]
Interst Recorded	$ 10,655
Days due within demand notice	2 days

Stockholders' Equity - Stock Is

Stockholders' Equity - Stock Issued upon Conversion of Debts (Details Narrative) - USD ($)

Mar. 27, 2019

Mar. 26, 2019

Mar. 25, 2019

Mar. 22, 2019

Mar. 20, 2019

Mar. 19, 2019

Mar. 18, 2019

Mar. 14, 2019

Mar. 13, 2019

Mar. 11, 2019

Mar. 08, 2019

Mar. 06, 2019

Mar. 05, 2019

Mar. 04, 2019

Feb. 28, 2019

Feb. 27, 2019

Feb. 26, 2019

Feb. 21, 2019

Feb. 19, 2019

Feb. 14, 2019

Feb. 13, 2019

Feb. 12, 2019

Feb. 11, 2019

Feb. 08, 2019

Feb. 07, 2019

Feb. 06, 2019

Jan. 30, 2019

Jan. 29, 2019

Jan. 24, 2019

Jan. 23, 2019

Jan. 18, 2019

Jan. 10, 2019

Jan. 07, 2019

Jan. 04, 2019

Dec. 20, 2018

Dec. 11, 2018

Dec. 07, 2018

Dec. 04, 2018

Nov. 23, 2018

Nov. 20, 2018

Lender 1

Common stock converted, amount

$ 5,996

Common stock converted, shares

200,000

Common stock converted, price per share

$ 0.03

Lender 2

Common stock converted, amount

$ 6,000

Common stock converted, shares

100,000

Common stock converted, price per share

$ 0.06

Lender 3

Common stock converted, amount

$ 6,370

Common stock converted, shares

140,000

Common stock converted, price per share

$ 0.0455

Lender 4

Common stock converted, amount

$ 10,920

Common stock converted, shares

600,000

Common stock converted, price per share

$ 0.0182

Lender 5

Common stock converted, amount

$ 33,100

Common stock converted, shares

2,500,000

Common stock converted, price per share

$ 0.0132

Lender 6

Common stock converted, amount

$ 13,240

Common stock converted, shares

400,000

Common stock converted, price per share

$ 0.0331

Lender 7

Common stock converted, amount

$ 7,250

Common stock converted, shares

500,000

Common stock converted, price per share

$ 0.0145

Lender 8

Common stock converted, amount

$ 7,500

Common stock converted, shares

2,500,000

Common stock converted, price per share

$ 0.0030

Lender 9

Common stock converted, amount

$ 4,800

Common stock converted, shares

800,000

Common stock converted, price per share

$ .0060

Lender 10

Common stock converted, amount

$ 15,000

Common stock converted, shares

2,000,000

Common stock converted, price per share

$ .0075

Lender 11

Common stock converted, amount

$ 4,800

Common stock converted, shares

800,000

Common stock converted, price per share

$ .0060

Lender 12

Common stock converted, amount

$ 21,063

Common stock converted, shares

2,808,401

Common stock converted, price per share

$ .0075

Lender 13

Common stock converted, amount

$ 15,771

Common stock converted, shares

2,102,777

Common stock converted, price per share

$ .0075

Lender 14

Common stock converted, amount

$ 6,384

Common stock converted, shares

1,200,000

Common stock converted, price per share

$ .0053

Lender 15

Common stock converted, amount

$ 10,675

Common stock converted, shares

2,500,000

Common stock converted, price per share

$ .0043

Lender 16

Common stock converted, amount

$ 15,000

Common stock converted, shares

3,333,333

Common stock converted, price per share

$ .0045

Lender 17

Common stock converted, amount

$ 2,880

Common stock converted, shares

2,000,000

Common stock converted, price per share

$ .0014

Lender 18

Common stock converted, amount

$ 7,385

Common stock converted, shares

4,102,778

Common stock converted, price per share

$ .0018

Lender 19

Common stock converted, amount

$ 8,288

Common stock converted, shares

6,400,000

Common stock converted, price per share

$ .0013

Lender 21

Common stock converted, amount

$ 115,405,699

Common stock converted, shares

6,411,111

Common stock converted, price per share

$ .0018

Lender 22

Common stock converted, amount

$ 11,366

Common stock converted, shares

3,165,833

Common stock converted, price per share

$ .0018

Lender 23

Common stock converted, amount

$ 8,026

Common stock converted, shares

6,314,194

Common stock converted, price per share

$ .0018

Lender 24

Common stock converted, amount

$ 5,760

Common stock converted, shares

4,458,889

Common stock converted, price per share

$ .0018

Lender 25

Common stock converted, amount

$ 9,639

Common stock converted, shares

4,000,000

Common stock converted, price per share

$ .0014

Lender 26

Common stock converted, amount

$ 14,491

Common stock converted, shares

7,650,000

Common stock converted, price per share

$ .0013

Lender 27

Common stock converted, amount

$ 8,513

Common stock converted, shares

8,050,556

Common stock converted, price per share

$ .0018

Lender 28

Common stock converted, amount

$ 15,573

Common stock converted, shares

5,284,722

Common stock converted, price per share

$ .0018

Lender 29

Common stock converted, amount

$ 14,817

Common stock converted, shares

8,651,667

Common stock converted, price per share

$ .0018

Lender 30

Common stock converted, amount

$ 9,216

Common stock converted, shares

8,231,667

Common stock converted, price per share

$ .0018

Lender 31

Common stock converted, amount

$ 10,586

Common stock converted, shares

6,400,000

Common stock converted, price per share

$ .0014

Lender 32

Common stock converted, amount

$ 10,586

Common stock converted, shares

5,881,172

Common stock converted, price per share

$ .0018

Lender 33

Common stock converted, amount

$ 15,557

Common stock converted, shares

8,642,778

Common stock converted, price per share

$ .0018

Lender 34

Common stock converted, amount

$ 14,137

Common stock converted, shares

10,116,215

Common stock converted, price per share

$ .0014

Lender 35

Common stock converted, amount

$ 10,836

Common stock converted, shares

8,600,000

Common stock converted, price per share

$ .0013

Lender 36

Common stock converted, amount

$ 11,953

Common stock converted, shares

8,243,268

Common stock converted, price per share

$ .0015

Lender 37

Common stock converted, amount

$ 6,480

Common stock converted, shares

6,000,000

Common stock converted, price per share

$ .0011

Lender 38

Common stock converted, amount

$ 10,608

Common stock converted, shares

7,577,379

Common stock converted, price per share

$ .0014

Lender 39

Common stock converted, amount

$ 8,131

Common stock converted, shares

10,100,000

Common stock converted, price per share

$ .0008

Lender 40

Common stock converted, amount

$ 13,809

Common stock converted, shares

12,007,730

Common stock converted, price per share

$ .0012

Lender 41

Common stock converted, amount

$ 14,046

Common stock converted, shares

12,213,852

Common stock converted, price per share

$ .0012

Lender 42

Common stock converted, amount

$ 9,821

Common stock converted, shares

12,200,000

Common stock converted, price per share

$ .0008

Lender 43

Common stock converted, amount

$ 13,837

Common stock converted, shares

12,032,165

Common stock converted, price per share

$ .0012

Lender 44

Common stock converted, amount

$ 12,880

Common stock converted, shares

14,000,000

Common stock converted, price per share

$ .0009

Lender 45

Common stock converted, amount

$ 13,816

Common stock converted, shares

12,014,009

Common stock converted, price per share

$ .0011

Lender 46

Common stock converted, amount

$ 10,000

Common stock converted, shares

15,231,130

Common stock converted, price per share

$ .0007

Lender 47

Common stock converted, amount

$ 10,633

Common stock converted, shares

9,246,374

Common stock converted, price per share

$ .0011

Lender 48

Common stock converted, amount

$ 13,765

Common stock converted, shares

17,100,000

Common stock converted, price per share

$ .0008

Lender 49

Common stock converted, amount

$ 1,813

Common stock converted, shares

2,931,643

Common stock converted, price per share

$ .0006

Lender 50

Common stock converted, amount

$ 8,092

Common stock converted, shares

7,036,426

Common stock converted, price per share

$ .0012

Lender 51

Common stock converted, amount

$ 15,000

Common stock converted, shares

13,043,478

Common stock converted, price per share

$ .0012

Lender 52

Common stock converted, amount

$ 17,620

Common stock converted, shares

19,152,700

Common stock converted, price per share

$ .0009

Lender 53

Common stock converted, amount

$ 20,258

Common stock converted, shares

17,630,730

Common stock converted, price per share

$ .0011

Lender 54

Common stock converted, amount

$ 16,100

Common stock converted, shares

20,000,000

Common stock converted, price per share

$ .0008

Lender 55

Common stock converted, amount

$ 24,136

Common stock converted, shares

20,987,826

Common stock converted, price per share

$ .0012

Lender 56

Common stock converted, amount

$ 15,000

Common stock converted, shares

14,285,714

Common stock converted, price per share

$ .0011

Lender 57

Common stock converted, amount

$ 16,088

Common stock converted, shares

19,152,700

Common stock converted, price per share

$ .00089

Lender 58

Common stock converted, amount

$ 19,258

Common stock converted, shares

18,340,504

Common stock converted, price per share

$ .0011

Lender 59

Common stock converted, amount

$ 18,671

Common stock converted, shares

17,781,905

Common stock converted, price per share

$ .0010

Lender 60

Common stock converted, amount

$ 18,375

Common stock converted, shares

25,000,000

Common stock converted, price per share

$ .0007

Lender 61

Common stock converted, amount

$ 15,029

Common stock converted, shares

Common stock converted, price per share

Stockholders' Equity - Stock _2

Stockholders' Equity - Stock Issued for Services (Details Narrative) - USD ($)	Dec. 03, 2018	Mar. 20, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 27, 2019	Dec. 11, 2018
Common stock, par value			$ 0.001	$ 0.001
Preferred stock shares, authorized			10,000,000
Preferred stock, par value			$ 0.001	$ 0.001
Common stock shares, authorized			4,000,000,000	1,125,000,000
Preferred stock, issued and outstanding			3,000,000
Common Stock issued, shares			597,064,715	90,000,000
Series A preferred stock, shares authorized			3,000,000
Series A preferred stock, par value per share			$ .001
Voting rights of series A holders			A Preferred Stock will participate on an equal basis per-share with holders of our common stock in any distribution upon winding up, dissolution, or liquidation. Holders of Series A Preferred Stock are entitled to vote together with the holders of our common stock on all matters submitted to shareholders at a rate of 1,000 votes for each share held. Holders of Series A Preferred Stock are entitled to convert each share held for 10 shares of common stock.
Common Stock issued, value			$ 597,065	$ 90,000
Prefessional fees expense				$ 153,104
Shares of common stock not issued					18,786,463
Consultant
Common Stock issued, shares	1,500,000
Common Stock issued, value	$ 172,500
Common Stock issued, price per share	$ 0.115
Prefessional fees expense			$ 69,000
Three Directors
Common Stock issued, shares						6,000,000
Common stock issued to each director	2,000,000
Common Stock issued, price per share						$ 0.0525
Prefessional fees expense	$ 315,000
Three Directors 2
Common Stock issued, shares		40,909,089
Common stock issued to each director		3,636,363
Common Stock issued, value		$ 90,000
Common Stock issued, price per share		$ .0022

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	12 Months Ended
	Mar. 31, 2019USD ($)	Jul. 16, 2018USD ($)
Interest Accrued	$ 3,261
Payment made to Pharma GP accounts payable		$ 133,284
Anderson [Member]
Advances from officer	17,740
Advances Outstanding	$ 68,106
Interst of Advance from officer	0
Promissory Note Issued	$ 32,608
Promissory Note Interest Rate	10.00%

Royalty Agreement (Details Narr

Royalty Agreement (Details Narrative)	12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Research and Development [Abstract]
Date of License Agreement	Apr. 4, 2017
Royaly Percentage	0.08
Minimum Royalty per month	$ 10,000
Royalty Expense	$ 80,000	$ 120,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Net Operating Loss tax basis	$ 1,077,790	$ 107,332
Provisions and accrued liabilities
Total deferred tax asset	1,077,790	107,332
Less valuation allowance	$ (1,077,790)	$ (107,332)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Taxes Details Narrative
Net Operating Loss	$ 1,077,790	$ 107,332
Corporate tax rate	21.00%	21.00%